Skip to content

Study · Not a test of the peptide alone · 2001

1 result

Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686.

Nagamine J, Nagata R, Seki H, Nomura-Akimaru N, Ueki Y, Kumagai K, Taiji M, Noguchi H

The Journal of endocrinology1 Dec 2001Cited by 33 (Europe PMC)

PMID11739014 (opens in a new tab)DOI10.1677/joe.0.1710481 (opens in a new tab)PepBankPUB-11739014
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MK-677 (ibutamoren).

  1. 01LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Activity measurement

    In human GHS receptor assays, SM-130686 inhibited radiolabeled MK‑677 binding dose-dependently, with IC(50)=1.2 nM.

    In plain wordsIn lab tests, SM-130686 blocked labeled MK‑677 binding to the human receptor.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseRadiolabeled MK-677 binding inhibition
    Study

    humann: not reported in source

    GHS receptor 1a
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    IC(50)
    1.2 nM
    SM-130686 inhibition of MK-677 binding

    Source sentences

    Summary
    SM-130686 dose-dependently inhibited the binding of radiolabeled ligand, (35)S-MK-677, to human GHS receptor 1a (IC(50)=1.2 nM).

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.